This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loughran, O.
Right arrow Articles by La Thangue, N. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loughran, O.
Right arrow Articles by La Thangue, N. B.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, March 2000, p. 2186-2197, Vol. 20, No. 6
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Apoptotic and Growth-Promoting Activity of E2F Modulated by MDM2

Öonagh Loughran and Nicholas B. La Thangue*

Division of Biochemistry and Molecular Biology, University of Glasgow, Glasgow G12 8QQ, United Kingdom

Received 26 July 1999/Returned for modification 15 September 1999/Accepted 24 November 1999

E2F integrates and coordinates cell cycle progression with the transcription apparatus through its cyclical interactions with important regulators of cellular proliferation, such as pRb, cyclins, and cdk's. Physiological E2F is a heterodimeric transcription factor composed of an E2F and a DP family member, and while E2F proteins can stimulate proliferation, certain members of the family are known to be endowed with growth-inhibitory and tumor suppressor-like activity. We have investigated the product of the human mdm2 oncogene, hDM2, and report on its ability to regulate E2F-dependent apoptosis in a fashion that is independent of p53. hDM2 can prevent p53-/- cells from entering E2F-dependent apoptosis, an outcome that is dependent upon the presence of the DP subunit. Cells rescued from apoptosis possess lower levels of E2F subunits, although the rescued cells show an increase in DNA synthesis and possess enhanced viability that reflects cooperation between E2F-DP and hMD2. Furthermore, the regulation of E2F activity correlates with an hDM2-dependent effect on the intracellular distribution of DP-1, since hDM2 causes the nuclear accumulation of DP-1. The control of E2F by hDM2 therefore has certain parallels with the targeted degradation by MDM2 of p53. However, the domains in hDM2 required for the regulation of E2F activity can be distinguished from those necessary for p53 degradation, suggesting that control of E2F and p53 by hDM2 may be mechanistically distinct. These experiments define a new level of interplay between E2F and hDM2 whereby hDM2 has a profound impact on the physiological consequences of E2F activation. They suggest that the oncogenic properties of hDM2 may in part be mediated by an antiapoptotic activity that converts E2F from a negative to a positive regulator of cell cycle progression and thereby retains E2F at a level that contributes to a continual state of growth stimulation.

* Corresponding author. Mailing address: Division of Biochemistry and Molecular Biology, Davidson Building, University of Glasgow, Glasgow G12 8QQ, United Kingdom. Phone: 0044 141 330 5514. Fax: 0044 141 330 5859. E-mail: n.lathangue{at}bio.gla.ac.uk.

Molecular and Cellular Biology, March 2000, p. 2186-2197, Vol. 20, No. 6
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Huart, A.-S., MacLaine, N. J., Meek, D. W., Hupp, T. R. (2009). CK1{alpha} Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability. J. Biol. Chem. 284: 32384-32394 [Abstract] [Full Text]  
  • Saha, A., Murakami, M., Kumar, P., Bajaj, B., Sims, K., Robertson, E. S. (2009). Epstein-Barr Virus Nuclear Antigen 3C Augments Mdm2-Mediated p53 Ubiquitination and Degradation by Deubiquitinating Mdm2. J. Virol. 83: 4652-4669 [Abstract] [Full Text]  
  • Gopinathan, L., Hannon, D. B., Peters, J. M., Vanden Heuvel, J. P. (2009). Regulation of Peroxisome Proliferator-Activated Receptor-{alpha} by MDM2. Toxicol Sci 108: 48-58 [Abstract] [Full Text]  
  • Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., Raffeld, M. (2009). MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma. Clin. Cancer Res. 15: 933-942 [Abstract] [Full Text]  
  • Sharma, S. V., Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21: 3214-3231 [Abstract] [Full Text]  
  • Kannemeier, C., Liao, R., Sun, P. (2007). The RING Finger Domain of MDM2 Is Essential for MDM2-mediated TGF-beta Resistance. Mol. Biol. Cell 18: 2367-2377 [Abstract] [Full Text]  
  • Toth, A., Nickson, P., Qin, L. L., Erhardt, P. (2006). Differential Regulation of Cardiomyocyte Survival and Hypertrophy by MDM2, an E3 Ubiquitin Ligase. J. Biol. Chem. 281: 3679-3689 [Abstract] [Full Text]  
  • Datta, A., Sen, J., Hagen, J., Korgaonkar, C. K., Caffrey, M., Quelle, D. E., Hughes, D. E., Ackerson, T. J., Costa, R. H., Raychaudhuri, P. (2005). ARF Directly Binds DP1: Interaction with DP1 Coincides with the G1 Arrest Function of ARF. Mol. Cell. Biol. 25: 8024-8036 [Abstract] [Full Text]  
  • Kulikov, R., Boehme, K. A., Blattner, C. (2005). Glycogen Synthase Kinase 3-Dependent Phosphorylation of Mdm2 Regulates p53 Abundance. Mol. Cell. Biol. 25: 7170-7180 [Abstract] [Full Text]  
  • Iwakuma, T., Lozano, G. (2003). MDM2, An Introduction. Mol Cancer Res 1: 993-1000 [Abstract] [Full Text]  
  • Ganguli, G., Wasylyk, B. (2003). p53-Independent Functions of MDM2. Mol Cancer Res 1: 1027-1035 [Abstract] [Full Text]  
  • Anderson, K., Potter, A., Baban, D., Davies, K. E. (2003). Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology. Brain 126: 2052-2064 [Abstract] [Full Text]  
  • Tsai, K. Y., MacPherson, D., Rubinson, D. A., Nikitin, A. Yu., Bronson, R., Mercer, K. L., Crowley, D., Jacks, T. (2002). ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc. Natl. Acad. Sci. USA 99: 16865-16870 [Abstract] [Full Text]  
  • Shimizu, H., Burch, L. R., Smith, A. J., Dornan, D., Wallace, M., Ball, K. L., Hupp, T. R. (2002). The Conformationally Flexible S9-S10 Linker Region in the Core Domain of p53 Contains a Novel MDM2 Binding Site Whose Mutation Increases Ubiquitination of p53 in Vivo. J. Biol. Chem. 277: 28446-28458 [Abstract] [Full Text]  
  • Hauck, L., Kaba, R. G., Lipp, M., Dietz, R., von Harsdorf, R. (2002). Regulation of E2F1-Dependent Gene Transcription and Apoptosis by the ETS-Related Transcription Factor GABP{gamma}1. Mol. Cell. Biol. 22: 2147-2158 [Abstract] [Full Text]  
  • Alarcon-Vargas, D., Ronai, Z.'e. (2002). p53-Mdm2--the affair that never ends. Carcinogenesis 23: 541-547 [Abstract] [Full Text]  
  • Strachan, G. D., Rallapalli, R., Pucci, B., Lafond, T. P., Hall, D. J. (2001). A Transcriptionally Inactive E2F-1 Targets the MDM Family of Proteins for Proteolytic Degradation. J. Biol. Chem. 276: 45677-45685 [Abstract] [Full Text]  
  • Sengupta, S., Wasylyk, B. (2001). Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev. 15: 2367-2380 [Abstract] [Full Text]  
  • Peng, Y., Chen, L., Li, C., Lu, W., Agrawal, S., Chen, J. (2001). Stabilization of the MDM2 Oncoprotein by Mutant p53. J. Biol. Chem. 276: 6874-6878 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»